Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Natalizumab Prior Auth | OpenPaye…
    Ask Trek AI about this page
    ModifiedEmpire BluecrossPolicy CC-0020

    Natalizumab Agents (Tysabri, Tyruko)

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0020 alerts

    Get alerted when Policy CC-0020 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical-necessity and prior-authorization coverage for Tysabri (natalizumab) and Tyruko (natalizumab-sztn) in adults with specified relapsing multiple sclerosis or moderately to severely active Crohn's disease, including Medicaid preferred-agent and step-therapy requirements.

    Policy Summary
    PayerEmpire Bluecross
    PolicyNatalizumab Agents (Tysabri, Tyruko)
    Policy CodePolicy CC-0020
    Change TypeModified
    Effective DateJul 22, 2026
    Last ReviewNov 14, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming the applicable indication, TOUCH/REMS enrollment, JCV antibody testing, and risk-benefit counseling.
    SourceLink
    POLICY UPDATE CHANGES

    ICD-10-CM code G37.9 was added for demyelinating disease of the central nervous system, unspecified, including clinically isolated syndromes.

    ICD-10-CM code G35 was removed and replaced by G35.A and G35.C1 for relapsing-remitting and active secondary progressive multiple sclerosis.

    Tyruko was added to the natalizumab clinical criteria and a quantity limit was added for natalizumab agents.

    HCPCS Q5134 was added for Tyruko and HCPCS J3490 and J3590 were removed.

    The policy history records step-therapy table updates on July 22, 2026 and May 1, 2026.

    Ocrevus Zunovo was added to the exclusion for concurrent use with other disease-modifying therapy criteria.

    2Natalizumab products covered

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1 vial/28 daysQuantity limit
    2Covered HCPCS codes
    4Current ICD-10 groups
    PMLBlack-box safety risk

    Coverage Criteria

    Initial approval criteria

    Covered when all applicable requirements are met:

    All applicable requirements

    • Indication pathway

      • Relapsing multiple sclerosis pathway

        • RMS diagnosis: The individual has relapsing multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease.
        • MS TOUCH/REMS: The individual is enrolled in and meets all conditions of the MS TOUCH/REMS Prescribing Program.
      • Crohn's disease pathway

        • Crohn's indication: The individual has moderate to severe Crohn's disease and is using Tysabri or Tyruko for induction and maintenance of clinical response and remission.
        • Prior therapy failure or intolerance: The individual has had an inadequate response to, or is unable to tolerate, conventional Crohn's disease therapies and TNF-alpha inhibitors.
        • CD TOUCH/REMS: The individual is enrolled in and meets all conditions of the CD TOUCH/REMS Prescribing Program.
    • JCV evaluation and counseling: A John Cunningham virus (JCV) antibody test has been performed, and the results, risks, and benefits have been discussed and understood.

    Medicaid multiple sclerosis criteria

    For Medicaid multiple sclerosis requests, approval may be based on any one of the following pathways:

    Medicaid MS pathways

    • Existing natalizumab therapy: Documentation is provided that the individual has been on Tysabri or Tyruko.
    • Preferred-agent trial: Documentation is provided that the individual has had a trial and inadequate response or intolerance to a preferred agent.
    • High disease activity despite disease-modifying therapy

      • Recent relapse: The individual has had at least one relapse in the previous year while on therapy.At least one relapse in the previous year

    Coverage is also not approved for individuals with a current or prior history of progressive multifocal leukoencephalopathy (PML) or a significantly compromised immune system, including HIV infection or AIDS, leukemia, lymphoma, or organ transplantation. Tysabri or Tyruko is not approved for concurrent use with chronic antineoplastics, immunosuppressants such as azathioprine, TNF-alpha inhibitors, or another multiple sclerosis disease-modifying agent.

    Coding

    HCPCSHCPCS
    J2323Injection, natalizumab, 1 mg [Tysabri]
    Q5134Injection, natalizumab-sztn (Tyruko), biosimilar, 1 mg
    ICD-10 DiagnosisICD-10
    G35.ARelapsing-remitting multiple sclerosis
    G35.C1Active secondary progressive multiple sclerosis
    G37.9Demyelinating disease of central nervous system, unspecified [clinically isolated syndromes]
    K50.00-K50.919Crohn's disease [regional enteritis]
    Z01.84Encounter for antibody response examination
    ICD-10 DiagnosisICD-10Covered
    G35.ARelapsing-remitting multiple sclerosis
    G35.C1Active secondary progressive multiple sclerosis
    G37.9Demyelinating disease of central nervous system, unspecified [clinically isolated syndromes]
    K50.00-K50.919Crohn's disease [regional enteritis]
    Z01.84Encounter for antibody response examination
    Historical coding updatesmixed
    G35ICD-10-CM code removed effective 9/30/25
    Q5134HCPCS code added effective 04/01/24
    J3490HCPCS code referenced as added and later removed in policy history
    J3590HCPCS code referenced as added and later removed in policy history
    Relapse while on therapy
    ThresholdAt least one relapse in the previous year while on therapy
    Evidence typeClinical relapse history
    UseOne required finding for documented high disease activity despite disease-modifying therapy
    Cranial MRI lesions
    ThresholdMultiple T2-hyperintense lesions in cranial MRI
    Evidence typeCranial MRI findings

    Provider Actions

    Documentation Required

    Clinical Review Required

    Clinical review is required when Tysabri (natalizumab) or Tyruko (natalizumab-sztn) is requested under the member’s medical benefit or is otherwise subject to clinical review, including prior authorization. Coverage is determined against the applicable medical-necessity criteria for the intended use.

    • Applies to Tysabri and Tyruko requests.
    • Review the diagnosis, intended use, and all applicable clinical criteria.
    Prior Authorization

    Prior Authorization Required

    Prior authorization and utilization-management review are required for natalizumab products when applicable under the member’s benefit plan. Submit the request before treatment is initiated or continued.

    • Affected products: Tysabri and Tyruko.
    • Plan-specific requirements may apply in addition to the clinical criteria.

    Policy Background

    Natalizumab carries a black-box warning for progressive multifocal leukoencephalopathy (PML), an opportunistic viral brain infection that can result in severe disability or death. PML risk is associated with treatment duration, prior immunosuppressant use, and anti-JCV antibodies. Treatment is distributed through the restricted TOUCH Prescribing Program; clinicians should monitor for PML and withhold treatment at the first suggestive sign or symptom.

    Definitions

    Relapsing multiple sclerosis (RMS)
    TermRelapsing multiple sclerosis (RMS)
    EncompassesClinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary progressive multiple sclerosis
    Policy contextNatalizumab is approved for adults with relapsing forms of multiple sclerosis
    Clinically isolated syndrome (CIS)
    TermClinically isolated syndrome (CIS)
    DefinitionA single clinical demyelinating event
    Relationship to MS

    Initial Therapy

    Initial natalizumab approval

    Initial therapy may be approved when all applicable requirements are met:

    Initial natalizumab requirements

    • Indication pathway

      • Relapsing multiple sclerosis pathway

        • The individual has relapsing multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease.
        • The individual is enrolled in and meets all conditions of the MS TOUCH/REMS Prescribing Program.
      • Crohn's disease pathway

        • The individual has moderate to severe Crohn's disease and is using Tysabri or Tyruko for induction and maintenance of clinical response and remission.

    Continuation Therapy

    Ongoing natalizumab therapy

    Continuation is covered when all of the following remain satisfied:

    Continuation requirements

    • Approved indication: Treatment continues for an approved relapsing multiple sclerosis or Crohn's disease indication.
    • TOUCH/REMS compliance: The individual remains enrolled in and compliant with the applicable MS or CD TOUCH/REMS Prescribing Program.
    • JCV testing and counseling: JCV antibody testing has been performed, and the results, risks, and benefits have been discussed and understood.

    Step Therapy

    Approval pathwayRequirementEvidence required
    Existing natalizumab therapyThe individual has been on Tysabri (natalizumab) or Tyruko (natalizumab-sztn).Documentation of prior use of the natalizumab agent.
    Preferred-agent trialThe individual has had a trial and inadequate response or intolerance to a preferred agent.Documentation of the preferred-agent trial and inadequate response or intolerance.
    High disease activity despite disease-modifying therapyThe individual has high disease activity despite treatment with a disease-modifying drug.All of the following: at least one relapse in the previous year while on therapy; multiple T2-hyperintense lesions in cranial MRI; and at least one gadolinium-enhancing lesion.
    Plan segment and effective datePreferred agents required before non-preferred therapyNon-preferred natalizumab agent(s)
    0MD, NV — effective 08/01/2025 through 01/01/2026Generic dimethyl fumarate, glatiramer, Glatopa, and teriflunomideTysabri
    0MD, NV — effective 08/01/2025 through 01/01/2026Generic dimethyl fumarate, glatiramer, and GlatopaTysabri and Tyruko

    Quantity Limits

    Tysabri quantity limit
    ProductTysabri (natalizumab) 300 mg/15 mL single-use vial
    Quantity limit1 vial
    FrequencyPer 28 days
    Tyruko quantity limit
    ProductTyruko (natalizumab-sztn) 300 mg/15 mL single-dose vial
    Quantity limit1 vial
    FrequencyPer 28 days

    Site of Care

    Note

    Administer by infusion

    Natalizumab is administered as an infusion. The policy does not specify a required infusion setting, so confirm the applicable operational requirements for the member and administering provider.

    Biosimilar Information

    Billing Rule

    Apply the same clinical criteria

    Tyruko (natalizumab-sztn) is biosimilar to Tysabri (natalizumab). The policy covers both agents subject to the same clinical criteria.

    • Tysabri HCPCS: J2323.
    • Tyruko HCPCS: Q5134.
    Policy Summary
    PayerEmpire Bluecross
    PolicyNatalizumab Agents (Tysabri, Tyruko)
    Policy CodePolicy CC-0020
    Change TypeModified
    Effective DateJul 22, 2026
    Last ReviewNov 14, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming the applicable indication, TOUCH/REMS enrollment, JCV antibody testing, and risk-benefit counseling.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider ActionsPolicy BackgroundDefinitionsInitial TherapyContinuation TherapyStep TherapyQuantity LimitsSite of CareBiosimilar Information
    Cranial MRI activity: Cranial MRI shows multiple T2-hyperintense lesions.Multiple T2-hyperintense lesions
  1. Gadolinium-enhancing lesion: The individual has at least one gadolinium-enhancing lesion.At least one gadolinium-enhancing lesion
  2. Use
    One required finding for documented high disease activity despite disease-modifying therapy
    Gadolinium-enhancing lesion
    ThresholdAt least one Gadolinium-enhancing lesion
    Evidence typeMRI lesion activity
    UseOne required finding for documented high disease activity despite disease-modifying therapy
    Step Therapy

    Plan-Level Preferred-Agent Requirement

    Even when clinical criteria are met, the benefit plan may require use of a preferred agent or agents before approving Tysabri or Tyruko. Verify the member’s plan-specific preferred-product requirements.

    • Preferred-agent requirements are benefit-plan dependent.
    • Preferred agents are products considered clinically comparable but preferred based on clinical evidence and cost effectiveness.
    Step Therapy

    Medicaid Natalizumab Step Therapy

    For Medicaid multiple sclerosis requests, Tysabri or Tyruko may be approved when the required natalizumab step-therapy pathway is met. Documentation must establish either continued use of a natalizumab agent or an inadequate response or intolerance to a preferred agent, along with high disease activity despite disease-modifying therapy.

    • Pathway 1: documentation that the individual has been on Tysabri or Tyruko.
    • Pathway 2: documented trial and inadequate response or intolerance to a preferred agent.
    • High disease activity documentation is also required.
    Step Therapy

    Plan-Specific Preferred-Agent Sequencing

    Medicaid preferred-agent sequencing varies by plan and effective date. Confirm the applicable state program, effective date, and preferred/non-preferred agent table before selecting Tysabri or Tyruko.

    • 08/01/2025: 0MD and NV list generic dimethyl fumarate, glatiramer, Glatopa, and teriflunomide among preferred alternatives; Tysabri and/or Tyruko are listed as non-preferred depending on the plan entry.
    • 01/01/2026: FL Healthy Kids lists teriflunomide as preferred; verify the current table for non-preferred-agent details.
    • Plan-specific sequencing may change with subsequent effective-date updates.
    Documentation Required

    Clinical and REMS Documentation

    Submit clinical documentation supporting the diagnosis and intended use, together with evidence of enrollment in and compliance with the applicable TOUCH/REMS program. RMS requests require MS TOUCH/REMS compliance; Crohn’s disease requests require CD TOUCH/REMS compliance.

    • RMS indications include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
    • For moderate to severe Crohn’s disease, document induction and maintenance use and inadequate response or intolerance to conventional therapies and TNFα inhibitors.
    • Document enrollment in and compliance with all conditions of the applicable TOUCH/REMS program.
    Documentation Required

    Medicaid Step-Therapy Documentation

    For Medicaid multiple sclerosis requests, provide documentation supporting the applicable step-therapy pathway. Records must show prior natalizumab use or a preferred-agent trial with inadequate response or intolerance.

    • Document the specific agent used and treatment history.
    • If a preferred agent was tried, document inadequate response or intolerance.
    Documentation Required

    High Disease Activity Evidence

    Document high disease activity despite treatment with a disease-modifying drug. The record must support all specified disease-activity findings.

    • At least one relapse in the previous year while on therapy.
    • Multiple T2-hyperintense lesions on cranial MRI.
    • At least one gadolinium-enhancing lesion.
    Denial Risk

    Excluded Clinical Circumstances

    Tysabri or Tyruko may not be approved for excluded clinical circumstances, including certain progressive disease states, effective alternate treatment, significant immune compromise, or prohibited combination therapy.

    • Primary progressive multiple sclerosis or non-active secondary progressive multiple sclerosis.
    • Currently responsive to and tolerating another treatment for multiple sclerosis or Crohn’s disease.
    • Current or prior progressive multifocal leukoencephalopathy, or a condition significantly compromising the immune system, including HIV/AIDS, leukemia, lymphoma, or organ transplantation.
    • Use with chronic antineoplastics, immunosuppressants, TNFα inhibitors, or other MS disease-modifying agents.

    Unsupported block type: denial_risk

    Unsupported block type: documentation

    Unsupported block type: step_therapy

    Billing Rule

    Quantity-Limit Exceedance

    The quantity limit is one 300 mg/15 mL single-use vial per 28 days for either Tysabri or Tyruko. Requests exceeding this limit require additional justification and may be denied.

    • Tysabri: 1 vial per 28 days.
    • Tyruko: 1 vial per 28 days.
    • Quantity-limit exception requests should include supporting clinical rationale.
    Denial Risk

    Criteria or Step Therapy Not Met

    Approval is at risk when the applicable clinical criteria or Medicaid step-therapy requirements are not met or are not documented. Confirm the indication, REMS requirements, preferred-agent sequence, disease-activity evidence, and quantity before submission.

    • Requests for excluded indications or circumstances may not be approved.
    • Medicaid requests lacking prior natalizumab use or preferred-agent trial documentation may not meet step therapy.
    • Requests exceeding one vial per 28 days may be denied without adequate justification.
    The event may be consistent with multiple sclerosis
    Progressive multifocal leukoencephalopathy (PML)
    TermProgressive multifocal leukoencephalopathy (PML)
    DefinitionAn opportunistic viral infection of the brain
    Safety significanceIt usually leads to death or severe disability and is a major safety risk of natalizumab
    G35.A
    CodeG35.A
    DescriptionRelapsing-remitting multiple sclerosis
    Coding systemICD-10-CM diagnosis code
    G35.C1
    CodeG35.C1
    DescriptionActive secondary progressive multiple sclerosis
    Coding systemICD-10-CM diagnosis code
    G37.9
    CodeG37.9
    DescriptionDemyelinating disease of central nervous system, unspecified [clinically isolated syndromes]
    Coding systemICD-10-CM diagnosis code
  3. The individual has had an inadequate response to, or is unable to tolerate, conventional Crohn's disease therapies and TNF-alpha inhibitors.
  4. The individual is enrolled in and meets all conditions of the CD TOUCH/REMS Prescribing Program.
  5. JCV evaluation and counseling: A JCV antibody test has been performed, and the results, risks, and benefits have been discussed and understood.
  6. Tyruko policy history
    ProductTyruko
    History updateQuantity limit added
    Recorded date09/11/2023